Theragnostics Ltd Expands Oncology Portfolio With Licensing of radioPARP Inhibitor

By In The News
February 28, 2019 in The Headlines

Recommended Posts

In The News

Posted February 28, 2019

- Share

Posted February 28, 2019

BRACKNELL, England and NEW YORK, Feb. 28, 2019 /PRNewswire/ -- Theragnostics Ltd (Theragnostics), UK, a company developing cutting edge diagnostic imaging and targeted radionuclide therapies, today announced that it has exclusively licensed worldwide rights to a radiolabelled PARP...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222047
2. Jaydee
  17801
3. deicer
  13355
4. Kip Powick
  12313
5. dagger
  9614
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  272.5k
- Total Posts
  
  565k

Sign In

Theragnostics Ltd Expands Oncology Portfolio With Licensing of radioPARP Inhibitor

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support